Daniel Peter Andersson News Today

Increased risk for cardiovascular morbidity and mortality seen with PDE5i use for erectile dysfunction in men with CAD

Study reveals men with heart disease taking erectile dysfunction drugs alongside nitrates face higher risk of early death, heart failure, and heart attack.

For men with stable CAD receiving nitrate medication, the use of PDE5i treatment for erectile dysfunction is associated with increased cardiovascular morbidity and mortality.

These medications are contraindicated but are often prescribed together

A new study suggests that men who take drugs commonly prescribed for erectile dysfunction and nitrates for chest pain have an increased risk of heart failure, early death and other negative outcomes.

Increased risk for cardiovascular morbidity and mortality seen with PDE5i use for erectile dysfunction in men with CAD.

But in a new study of more than 60,000 men, taking this medication along with nitrates increased risks of negative health outcomes such as heart failure and early death, according to a new study.

Prescribing phosphodiesterase type 5 inhibitors and nitrates together may increase the risk of morbidity and mortality for patients over time.

A Swedish study reveals higher risks for men with cardiovascular disease using erectile dysfunction drugs (PDE5 inhibitors) alongside nitrate medication, potentially increasing morbidity and mortality.

A new study found increased risks of negative health outcomes such as heart failure and early death when taking the ED drug known as PDE5i along with nitrates, a common drug for chest pain.